Abcam, ab273380, Human CXCR5 knockout Raji cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
CXCR5 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 19 bp deletion in exon 2. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:Raji,
Species or organism:Human,
Tissue:Lymphatic,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 19 bp deletion in exon 2,
Disease:Lymphoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-CXCR5, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CXCR5 also known as CD185 is a chemokine receptor with a mass of approximately 43 kDa. It is part of the G protein-coupled receptor family and is widely expressed on follicular B helper T (Tfh) cells B cells and a subset of circulating blood cells. CXCR5 is recognized as a marker for Tfh cells which are critical for the function and maturation of B cells within germinal centers. In tissues CXCR5 expression appears prominently in regions where immune cell interactions facilitate immune and inflammatory responses.
Biological function summary
CXCR5 serves a significant role in directing B cells and Tfh cells to lymphoid tissues by interacting with its ligand CXCL13. This interaction involves recruitment and organization of B cells into follicles within secondary lymphoid organs. The presence of CXCR5 allows B cells and Tfh cells to navigate the follicular zones efficiently enhance antigen-specific immune responses and contribute to long-lived humoral immunity. CXCR5 functions as part of a complex that includes signaling pathways influencing cellular movements and location.
Pathways
CXCR5 plays a significant part in the immune system's trafficking pathways particularly within the crosstalk between chemokines and their receptors. CXCR5 expression facilitates the CXC chemokine pathway which important for positioning immune cells within lymphoid organs. Additionally CXCR5 interacts with proteins such as CXCL13 working together to pattern the architecture of germinal centers where affinity maturation and class switching of antibodies occur critical processes in adaptive immunity.
CXCR5 has been implicated in autoimmune diseases and certain lymphomas. For example aberrant CXCR5 expression is linked to the pathogenesis of diseases like systemic lupus erythematosus (SLE) where it might contribute to immune dysregulation and chronic inflammation. In the context of certain lymphomas CXCR5's role in lymphoid organ architecture and cell migration becomes even more relevant. Its expression often parallels the presence of CXCL13 hinting at a network of interactions promoting tumor survival and growth within lymphoid landscapes. Understanding these relationships can offer insight into developing therapeutic strategies potentially involving CXCR5 inhibitors or anti-CXCR5 antibodies to address these diseases.